Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients

Metabolism: Clinical and Experimental

Volumn 58, Issue 11, 2009, Pages 1624-1628

  Nakamura, Tsukasa ^a   Sato, Eiichi ^a   Fujiwara, Nobuharu ^a   Kawagoe, Yasuhiro ^a   Ueda, Yoshihiko ^b   Suzuki, Tsukasa ^b   Yamada, Shingo ^c   Takeuchi, Masayoshi ^d   Fukami, Kei ^e   Ueda, Seiji ^e   Adachi, Hisashi ^e   Matsui, Takanori ^e   Okuda, Seiya ^e   Yamagishi, Sho ichi ^e  

^a Shinmatsudo Central General Hospital   (Japan)

^b DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHINO TEST CORPORATION   (Japan)

^d HOKURIKU UNIVERSITY   (Japan)

^e KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HEMOGLOBIN A1C; HIGH MOBILITY GROUP B1 PROTEIN; N(G),N(G) DIMETHYLARGININE; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ARGININE; DRUG DERIVATIVE; IMMUNOGLOBULIN RECEPTOR; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE;

ADULT; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEINURIA; VASCULITIS; BLOOD; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; HEMODYNAMICS; PHYSIOLOGY; REGRESSION ANALYSIS;

ADULT; ARGININE; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMODYNAMICS; HMGB1 PROTEIN; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; RECEPTORS, IMMUNOLOGIC; REGRESSION ANALYSIS;

EID: 70449715636     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.05.018     Document Type: Article

References (34)

1. Yamagishi S., Ueda S., Nakamura K., Matsui T., and Okuda S. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des 14 (2008) 2613-2618
2. Ueda S., Yamagishi S., Matsumoto Y., Fukami K., and Okuda S. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 11 (2007) 115-121
3. Caglar K., Yilmaz M.I., Sonmez A., et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 70 (2006) 781-787
4. Yilmaz M.I., Saglam M., Caglar K., et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47 (2006) 42-50
5. Yamagishi S., Nakamura K., Matsui T., Noda Y., and Imaizumi T. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 14 (2008) 487-495
6. Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med 7 (2007) 711-724
7. Yamagishi S., and Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11 (2005) 2279-2299
8. Kilhovd B.K., Berg T.J., Birkeland K.I., Thorsby P., and Hanssen K.F. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22 (1999) 1543-1548
9. Nakamura K., Yamagishi S., Matsui T., et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med 7 (2007) 188-190
10. Nakamura K., Yamagishi S., Adachi H., et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 23 (2007) 368-371
11. Nakamura K., Yamagishi S., Adachi H., et al. Serum levels of soluble form of receptor for advanced glycation end products are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvascular Res 76 (2008) 52-56
12. Yamagishi S., Matsui T., and Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 8 (2007) 1138-1143
13. Yan X.X., Lu L., Peng W.H., et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis (2009) 10.1016/j.atherosclerosis.2008.12.016
14. Lu C.W., Xiong Y., and He P. Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein. Nitric Oxide 16 (2007) 94-103
15. Lin K.Y., Ito A., Asagami T., et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106 (2002) 987-992
16. Imai E., Horio M., Nitta K., et al. Estimation of glomerular filtration rate by MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11 (2007) 41-50
17. Ueda S., Kato S., Matsuoka H., et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine. Circ Res 92 (2003) 226-233
18. Takeuchi M., Makita Z., Bucala R., et al. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 6 (2000) 114-125
19. Jinnouchi Y., Yamagishi S., Takeuchi M., et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 6 (2006) 191-193
20. Nakamura K., Yamagishi S., Adachi H., et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 13 (2007) 185-189
21. Yamada S., Yakabe K., Ishii J., Imaizumi H., and Maruyama I. New high mobility group box 1 assay system. Clin Chim Acta 372 (2006) 173-178
22. Yamada S., and Maruyama I. HMGB1, a novel inflammatory cytokine. Clin Chim Acta 375 (2007) 36-42
23. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 4 (1998) 1025-1031
24. Bucciarelli L., Wendt T., Qu W., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106 (2002) 2827-2835
25. Humpert P.M., Djuric Z., Kopf S., et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovascular Diabetology 6 (2007) 9
26. Raucci A., Cugusi S., Antonelli A., et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22 (2008) 3716-3727
27. Tanaka N., Yonekura H., Yamagishi S., et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275 (2000) 25781-25790
28. Yamagishi S., Matsui T., Nakamura K., Takeuchi M., and Inoue H. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Protein Pept Lett 15 (2008) 850-853
29. Fukami K., Ueda S., Yamagishi S., et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 66 (2004) 2137-2147
30. Yamagishi S., Amano S., Inagaki Y., et al. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes. Mol Med 8 (2002) 546-550
31. Neeper M., Schmidt A.M., Brett J., et al. Cloning and expression of a cell surface receptor for advanced glycation end products of proteins. J Biol Chem 267 (1992) 14998-15004
32. Hori O., Brett J., Slattery T., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270 (1995) 25752-25761
33. Bruchfeld A., Qureshi A.R., Lindholm B., et al. High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med 14 (2008) 109-115
34. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305